Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Targeting mitotic regulators in cancer as a strategy to enhance immune recognition.

Gregorczyk M. and Parkes EE., (2023), DNA Repair (Amst), 132

STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.

Pencik J. et al, (2023), Mol Cancer, 22

Non-cell-autonomous cancer progression from chromosomal instability.

Li J. et al, (2023), Nature, 620, 1080 - 1088

cGAS-STING signalling in cancer: striking a balance with chromosomal instability.

Beernaert B. and Parkes EE., (2023), Biochem Soc Trans

Non-cell-autonomous cancer progression from chromosomal instability

Li J. et al, (2023), NATURE

A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.

Fletcher CE. et al, (2022), Mol Cancer, 21

When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.

van Vugt MATM. and Parkes EE., (2022), Trends Cancer, 8, 174 - 189

Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.

Parkes EE. et al, (2022), Br J Cancer, 126, 247 - 258

A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments

Kopetz S. et al, (2022), JOURNAL OF CLINICAL ONCOLOGY, 40

A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA).

Lillie T. et al, (2022), CANCER RESEARCH, 82

A multicenter phase 1a/b study of NG-350A, a tumor-selective anti-CD40-antibody expressing adenoviral vector, and pembrolizumab in patients with metastatic or advanced epithelial tumors (FORTIFY).

Lillie T. et al, (2022), CANCER RESEARCH, 82

Chromosomal instability shapes the tumor microenvironment through a chronic ER-stress response

Li J. et al, (2022), CANCER RESEARCH, 82

NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors

Lillie T. et al, (2022), JOURNAL OF CLINICAL ONCOLOGY, 40

The tumor microenvironment and immune responses in prostate cancer patients.

Kwon JTW. et al, (2021), Endocr Relat Cancer, 28, T95 - T107

Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors.

Harrington K. et al, (2021), CANCER RESEARCH, 81

The clinical and molecular significance associated with STING signaling in breast cancer.

Parkes EE. et al, (2021), NPJ Breast Cancer, 7

Development of Immunotherapy Combination Strategies in Cancer.

Yap TA. et al, (2021), Cancer Discov, 11, 1368 - 1397

Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.

Li J. et al, (2021), Cancer Discov, 11, 1212 - 1227

Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.

Willenbrock F. et al, (2021), Br J Cancer, 124, 581 - 586

Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.

Philippou Y. et al, (2020), Br J Cancer, 123, 1089 - 1100

Load More